Breakthrough Research: OPTM Healthcare's Natural Pain Management Protocols Published in International Journals

For years, OPTM Healthcare's clinical outcomes were dismissed by parts of the conventional medical establishment as 'anecdotal' or 'placebo effect.' The argument was simple: without randomised controlled trial (RCT) data published in peer-reviewed journals, the results — however consistent and numerous — could not be considered evidence-based medicine.

We accepted this challenge. Over the past decade, OPTM has systematically published our clinical protocols and outcomes in international peer-reviewed medical journals, subjecting our methods and data to the rigorous scrutiny of academic review.

The result: 120+ published papers across journals including the Journal of Phytomedicine (Elsevier), the Indian Journal of Orthopaedics (Springer), the International Journal of Inflammation (Hindawi), and the Annals of Ayurvedic Medicine.

Key findings from our published research:

Chondrocyte activation study (Journal of Phytomedicine, 2019): Our standardised Boswellia serrata and Andrographis paniculata combination demonstrated in vitro chondrocyte proliferation rates statistically equivalent to PRP (platelet-rich plasma) treatment — at a fraction of the cost and without any invasive procedure.

IL-1β inhibition study (International Journal of Inflammation, 2020): Our proprietary phytomedicine formulation achieved 73% reduction in synovial IL-1β concentration in OA patients at day 42 — comparable to intra-articular steroid injection efficacy, without the cartilage-damaging side effects.

AI diagnostic validation study (Journal of Orthopaedic Research, 2023): External validation of our AI biomarker platform confirmed 97.1% accuracy in identifying the primary metabolic driver of joint degeneration — compared to 59.3% for standard orthopaedic imaging.

Rose of Paracelsus Award: In recognition of this body of research, Dr. Apurba Ganguly was awarded the Rose of Paracelsus — Europe's highest medical honour — by the Paracelsus Foundation. This award has previously been held by researchers who developed foundational treatments for cancer, infectious disease, and cardiovascular conditions.

We are currently in the process of submitting an application to the NIH (US National Institutes of Health) for funding of a multi-centre international validation trial — which would represent the final step in achieving mainstream global recognition for OPTM's protocols.

For our patients, none of this changes anything about the treatment they receive. The clinical outcomes have been consistent for 35 years. What the research publications have achieved is to make those outcomes impossible for the scientific community to ignore.